Navigation Links
FDA Accepts Tasimelteon New Drug Application For Priority Review In The Treatment Of Non-24-Hour Disorder In The Totally Blind
Date:7/29/2013

cessary to entrain the master body clock in the brain with the 24-hour day-night cycle.  Most people have a master body clock that naturally runs longer than 24-hours and light is the primary environmental cue that resets it to 24 hours each day.  Individuals with Non-24 have a master body clock that is not reset, and continually delays, resulting in prolonged periods of misalignment between their circadian rhythms and the 24-hour day-night cycle, including the timing of melatonin and cortisol secretion.  As a result of this misalignment, Non-24 is associated with significant disruption of the sleep-wake cycle and impairments in social and occupational functioning, and marked subjective distress.  Currently there is no approved treatment for Non-24.  For more information on Non-24, please visit www.Non-24.com.

About Tasimelteon
Tasimelteon is a circadian regulator in development for the treatment of Non-24.  Tasimelteon is a dual melatonin receptor agonist (DMRA) with selective agonist activity at the MT1 and MT2 receptors.  Tasimelteon aims to reset the master body clock in the suprachiasmatic nucleus (SCN), resulting in the entrainment of the body's melatonin and cortisol rhythms to align to the 24-hour day-night cycle.  The patent claiming tasimelteon as a new chemical entity extends through December 2022, assuming a 5-year extension to be granted under the Hatch-Waxman Act.  Tasimelteon has been granted orphan drug designation for the treatment of Non-24 from both the U.S. and the European Union.  Tasimelteon has not been approved by the FDA or any other regulatory authority.

About Tasimelteon NDA
Summary of Efficacy
The efficacy of tasimelteon as a circadian regulator of the master body clock in the treatment of Non-24 was studied in two randomized, double-masked, placebo-controlled, multicenter, parallel-group trials, SET (Safety and E
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
2. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
3. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
4. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
5. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
6. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
7. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
8. Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
9. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
10. EPGL Medical Invents Self Powered Contact Lenses for Medical and Consumer Applications
11. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... China , Jan. 23, 2015 Tianyin Pharmaceutical ... company that specializes in the development and sale of ... generics and active pharmaceutical ingredients (API) today announced the ... (JCM) API operation. 1. Following the September ...
(Date:1/22/2015)... RMD ) today announced results for its quarter ... million, a 10 percent increase compared to the quarter ended ... currency basis). Net income was $91.2 million, an increase of ... Diluted earnings per share for the quarter were $0.64, an ...
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical Research, ... and obesity, announced today a new textbook,  Translational Research ... by Springer, a leading global scientific publisher. ... illustrate techniques for use in early phase clinical studies ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... BRISBANE, Australia, Feb. 13 Progen,Pharmaceuticals Limited ... efficacy results from a phase 2 investigator-initiated ... agent Taxotere(R),(docetaxel) administered to patients with prostate ... Sydney Haematology and Oncology Clinics, the,principal investigator ...
... demonstrates,for the first time that embryonic stem cells can ... finding which is an important step,in the utilization of ... bone marrow transplantation. This hopeful news for patients with,severe ... was prepublished online in Blood, the official journal of ...
Cached Medicine Technology:Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium 2Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium 3A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds 2A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds 3
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering ... follow it on Facebook, Twitter, and Pinterest. The fans will ... draws a lottery every week. , Moreover, the company has ... Click Angelweddingdress homepage for more information. , ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... connect with schools and education information. , ... ... pursuing medical assisting degrees, choosing the right school just got ... website ( http://www.mymedicalassistingdegree.com/ ), students can learn about medical assistant ...
... monitoring means type 1 patients can avoid retinopathy, study ... good control over one,s blood sugar levels can help ... serious disorder that damages the eye,s retina, researchers say. ... that confirms prior large studies. The findings were published ...
... 2008 Thousands of the world,s top scientists and ... present their latest research at the 58th Annual Meeting ... Philadelphia, Pennsylvania on November 11-15, 2008. , A ... Meeting will provide information about important new research findings ...
... meat and processed meats, researchers say , , FRIDAY, Nov. 14 ... such as red and processed meats -- may be a ... the conclusion of a U.S. National Cancer Institute study that ... about their eating habits over eight years. , Previous research ...
... journal published by The Feinstein Institute for ... functioning and disease pathogenesis at the molecular ... to use that knowledge in the design ... treatment, prognosis, and prevention. Featured in ...
... and athletic enhancer, sales of acai products have dramatically increased in the ... from acai palms that may reach heights in excess of 60 feet ... palm. , ... Green Bay, WI (PRWEB) November 14, 2008 -- Though ...
Cached Medicine News:Health News:MyMedicalAssistingDegree.com Provides School-Search Help for Students 2Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 2Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 3Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 4Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 5Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 6Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 7Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 8Health News:Saturated Fats Linked to Cancer of Small Intestine 2Health News:Researchers Tackle CLL, Diabetes and Trauma-Hemorrhage, 2Health News:Research Finds The Brazilian Acai Absorbs Much Better Than Any Other Fruit 2
Binocular indirect ophthalmic lenses. Small pupil diagnosis & treatment....
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
Binocular indirect ophthalmic lenses. Ultra magnification of posterior pole....
... Volk's super ... biomicroscopy lenses. Examination ... Provide unprecedented fundus ... addressing maximum potential ...
Medicine Products: